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DevelopmentThe biosynthesis of mucin-type O-linked glycans in animals is initiated by members of the large family of poly-
peptide N-acetylgalactosaminyltransferases (GalNAc-Ts), which play important roles in embryogenesis, organo-
genesis, adult tissue homeostasis and carcinogenesis. Until now, the mammalian forms of these enzymes have
been the best characterized. However, two N-acetylgalactosaminyltransferases (xGalNAc-T6 and xGalNAc-
T16) from the African clawed frog (Xenopus laevis), which are most homologous to those encoded by the
human GALNT6 and GALNT16 (GALNTL1) genes, were shown to have contrasting roles in TGF-β/BMP signaling
in embryogenesis. In this study we have examined these two enzymes further and show differences in their
in vivo function during X. laevis embyrogenesis as evidenced by in situ hybridization and overexpression exper-
iments. In terms of enzymatic activity, both enzymes were found to be active towards the EA2 peptide, but dis-
play differential activity towards a peptide based on the sequence of ActR-IIB, a receptor relevant to TGF-β/BMP
signaling. In summary, these data demonstrate that these two enzymes from different branches of the N-
acetylgalactosaminyltransferase do not only display differential substrate speciﬁcities, but also speciﬁc and dis-
tinct expression pattern and biological activities in vivo.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
There are various molecular markers distinguishing animals from
plants, fungi, protists and bacteria. Amongst these are glycan modiﬁca-
tions of peptides and proteins which appear to be rather restricted to
the Metazoan lineage—such as proteoglycans based on O-linked xylose
(Xyl) linked to serine ormucins based onO-linkedN-acetylgalactosamine
(GalNAc) linked to serine or threonine. These types of animal-speciﬁc gly-
cosylation are also strongly evolutionarily conserved throughout the ani-
mal kingdom, indicating a speciﬁc and fundamental role in animal
development and physiology. Indeed, gel-forming mucins emerged
early during metazoal evolution and are found, e.g., in the cnidaria
(Lang et al., 2007). Themodiﬁcation of proteins by GalNAc residues is ini-
tiated by the action of a family of N-acetylgalactosaminyltransferases
(ppGalNAc-T, ppGaNTase or GalNAc-T enzymes encoded by GALNTinyltransferase.
.
ring Research Center, Nanjing
t, Berlin, Germany.
. This is an open access article undergenes in vertebrates; EC 2.4.1.41). Recent data from model organisms
such as Drosophila melanogaster and Xenopus laevis, as well as the discov-
ery of the basis of familial tumoral calcinosis, have indicated that themod-
iﬁcation of proteins by N-acetylgalactosamine to form ‘mucin-type’ O-
linked oligosaccharides is required for normal animal development. For
instance, lethal mutations are associated with two D. melanogaster N-
acetylgalactosaminyltransferase genes (pGaNT35A and pGaNT5) (Ten
Hagen and Tran, 2002; Tran et al., 2012), whereas the association of mu-
tations in the human GALNT3 gene with familial tumoral calcinosis also
highlights the importance of this type of protein modiﬁcation (Topaz
et al., 2004). Furthermore, it has been suggested that the modiﬁcation of
ﬁbronectin by mammalian GalNAc-T6 may have a role in breast cancer
development and progression (Park et al., 2011).
The in silico prediction of which sites may become O-glycosylated
proved difﬁcult and only rather vague ‘consensus’ sequences for this
modiﬁcation were proposed (Wilson et al., 1991; O'Connell et al., 1992;
Hansen et al., 1995); many assays with partially-puriﬁed enzymes
were also performed in order to deﬁne these sequences by in vitro
means (Cottrell et al., 1992; O'Connell et al., 1992). In retrospect, it is ob-
vious that such attempts at deﬁning consensus sequenceswould fail, due
to the subsequent isolation of a large number of cDNAs encoding N-
acetylgalactosaminyltransferase isoforms from mammalian, insect andthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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identiﬁed by, especially, the Tabak, Clausen and Narimatsu laboratories
(Bennett et al., 2012). Over the years, overlapping substrate speciﬁcities,
requirements for pre-glycosylated substrates and variable gene expres-
sion patterns have been determined for the twenty or so mammalian
members of this enzyme family. Activity has been reported for some sev-
enteen mammalian N-acetylgalactosaminyltransferases, the latest being
for GalNAc-Ts 15–18 (Cheng et al., 2004; Peng et al., 2010; Raman
et al., 2012). Data are still awaited to deﬁne the speciﬁcities of human
GalNAc-T8, -T19, and -T20; potentially GalNAc-T18, a member of the
vertebrate-speciﬁc Y subfamily, modulates the activity of othermembers
of this enzyme family (Li et al., 2012), although a low activitywas detect-
ed in a different study (Raman et al., 2012). Considering the partial func-
tional redundancy of these enzymes, a challenge has been to match the
biochemical knowledge with their biological signiﬁcance; this has also
been complicated by differences in nomenclature and numbering be-
tween different laboratories.
In a previous study it was shown that an N-acetylgalactosaminyl-
transferase from X. laevis plays an important role in the regulation of
early embryogenesis (Herr et al., 2008). The gene was described
to display the highest identity with the human GALNTL1 (N-
acetylgalactosaminyltransferase-like 1 gene, now known as
GALNT16; the enzyme is hereafter deﬁned as xGalNAc-T16). Specif-
ically, this amphibian GalNAc-T16 was shown to regulate the TGF-
β/BMP (tissue growth factor-β/bone morphogenetic protein)
pathway during early embryonic development, potentially modify-
ing and modulating the activity of a TGF-β receptor known as ActR-
IIB (Activin A receptor type IIB) (Herr et al., 2008). A second am-
phibian N-acetylgalactosaminyltransferase displaying the highest
homology to human GalNAc-T6 also shows a relationship to BMP
signaling, since its in vivo expression during embryogenesis coin-
cides with high endogenous BMP signaling and is also dependent
on the activity of the BMP pathway. xGalNAc-T6 and xGalNAc-
T16 are highly homologous to isoforms in other species, e.g. the
human isoforms GalNAc-T6 and GalNAc-T16 both show N70% se-
quence similarity to the frog isoforms (Herr et al., 2008).
Whereas themammalian formsofN-acetylgalactosaminyltransferases
have been generally well characterized in terms of their enzymology,
there are few data on amphibian forms of these enzymes; considering
the developmental signiﬁcance of xGalNAc-T6 and xGalNAc-T16, it was
sought to biochemically characterize these upon expression in Pichia
pastoris. Our biochemical analysis of these two proteins would suggest
that ActR-IIB is indeed an excellent substrate for xGalNAc-T16, but not
xGalNAc-T6. In addition to the distinct and speciﬁc substrate speciﬁcities
of these two N-acetylgalactosaminyltransferases, they also display com-
plex but very different expression pattern in the early Xenopus embryo
as well as different biological activities in overexpression studies. This
comprehensive study, thereby, demonstrates differential biochemical
and biological functions of two N-acetylgalactosaminyltransferases dur-
ing early vertebrate embryogenesis.
2. Experimental procedures
2.1. Developmental studies
In vitro fertilization, embryo and explant culture, microinjection of
synthetic mRNA, in situ hybridization and RT-PCR analysis were per-
formed as described (Herr et al., 2008). Full-length cDNA IMAGE con-
sortium clones encoding xGalNAc-T6 and xGalNAc-T16 were obtained
from the RZPD (see above) and the open reading frames cloned by
PCR into pCS2+. For mRNA synthesis, the constructs were cut with
NotI and transcribed with SP6 RNA polymerase using the mMessage
mMachine Kit (Ambion, Austin, TX). Probes for in situ hybridization
were directly generated from the GalNAc-T6 and -T16 cDNA clones
cut with KpnI and BamHI, respectively and transcribed with T7 poly-
merase. For RT-PCR analysis, embryos were injected in the animalpole of all four blastomeres at the 4-cell stages with 100 pg noggin or
400 pg op1 mRNA, explants isolated at stage 9 and cultured until
stage 24. The primers for the RT-PCR analysis of ectodermal explants
were described elsewhere (Herr et al., 2008). Expression of α-actin
served as a control for mesoderm contamination and odc as a loading
control.
2.2. Cloning of X. laevis N-acetylgalactosaminyltransferase cDNA fragments
Using two previously-described full length clones as templates
(Herr et al., 2008), fragments of the cDNAs encoding the predicted lu-
menal regions of the X. laevis xGalNAc-T6 and xGalNAc-T16 (respec-
tively previously designated as xGalnt-6 and xGalntl-1) were isolated
by PCR using KOD Polymerase and two primer pairs: xGalnt-6/1/EcoRI
(cggaattcaaagatgttgggaatggag) with xGalnt-6/2/XbaI (tgctctagatttag
ctgaaaccccagc) and xGalnt-16/1/EcoRI (cggaattccaggacagcaagcccca)
with xGalnt-16/2/XbaI (tgctctagactcatgtagcctgaagtatc). The templates
were two IMAGE EST clones (BC110706 and BM192636) obtained
from RZPD (now SourceBioscience, Berlin); the isolated PCR fragments
were puriﬁed using a GFX kit (GE Healthcare) and digested with EcoRI
and XbaI prior to ligation into pPICZαFLAGC3 (a variant of the
Invitrogen pPICZαC plasmid prepared by inverse PCR to generate a
form encoding an N-terminal FLAG tag) cut with the same enzymes
(Nemčovičová et al., 2013). Positive clones were veriﬁed by DNA se-
quencing and linearized before transformation into P. pastoris GS115.
Phylogenetic studies were based on comparing GalNAc-T isoforms of
frog, human, bovine, mouse, chicken and zebraﬁsh origin using one-
click analysis on phylogeny.fr (Dereeper et al., 2008).
2.3. Recombinant expression of N-acetylgalactosaminyltransferases
Pre-cultures of selected independent recombinant P. pastoris clones
were set up in BMGYmedium containing 100 μg/mL zeocin and inoculat-
ed overnight at 30 °Cwith continuous shaking (250 rpm). The cells were
then collected by centrifugation (10 min, 1500 g, 4 °C), washed and re-
suspended in the induction medium containing 1% methanol (BMMY
medium) to an OD600 value of 1.0; depending on the scale of fermenta-
tion, 50 or 400 mL of these suspensions was transferred into fresh fer-
mentation ﬂasks, and incubated further at 30 °C with continuous
shaking (250 rpm). After 24, 48 and 72 h additional methanol was
added to maintain the concentration of 1% (v/v), and the induction tem-
perature was decreased to 16 °C. 24 h after the last inductionwithmeth-
anol, the cultureswere centrifuged at 4000 g for 10min at 4 °C; for large-
scale fermentations, residual particles in the culture supernatantwere re-
moved using a ﬁlter syringe (0.45 μm pore size). The supernatants were
then concentrated approximately 100-fold (using centrifugal concentra-
tors with MR = 30 kDa cut-off), and stored in 60 μL-aliquots in the
−80 °C freezer. Expression of the N-acetylgalactosaminyltransferases
was proven by tryptic peptide mass ﬁngerprinting as well as byWestern
blotting with monoclonal anti-FLAG antibody (Sigma Aldrich).
2.4. Protein quantiﬁcation using bicinchoninic acid (BCA)
Protein quantiﬁcation was performed using a microplate BCA pro-
tein assay (Thermo Pierce). Concentrated supernatant containing active
xGalNAcT isoforms was quantiﬁed with the BCA assay in undiluted, 1:5
and 1:25 dilutions, and the absorbance was analysed at 562 nm, and
compared with the absorbance of BSA-standard concentrations (25–
2000 μg/mL BSA). The protein concentration was 17.9 mg/mL for
xGalNAc-T6 and 6.7 mg/mL for xGalNAc-T16, respectively.
2.5. Assays for N-acetylgalactosaminyltransferase activity
Typically, enzyme activity was tested using a mixture of 1 mM pep-
tide (for sequences see Table 1), 1.5 mMUDP-GalNAc, 20 mMMES (pH
7.5), 10 mMMnCl2, 1 U CIP (Calf Intestinal Alkaline Phosphatase, NEB)
Table 1
Peptide speciﬁcities of the frog xGalNAc-T isoforms. Masses indicated with (m/z) corre-
spond to the sodium adduct of the peptides with those of products of successful glycosyl-
ation reactions in bold; the indices beside the roundedm/z values indicate the number of
transferred GalNAc residues per peptide after 16 h of incubation. The asterisk indicates
that these species were detected only in low amounts. RNApII and neuroglycan peptides
are acceptors for O-GlcNAc and O-xylosyl transferases, but were demonstrably not sub-
strates for either enzyme.




Muc1fr1 1023 GAPGSTAPPAGK 12351 1023
Muc1fr2 1075 GAHGVTSAPAGK 12781 1075
Muc1fr3 1134 GAAPDTRPAAGK 1134 1134
OPSS1 1285 GAGAPGPTPGPAGAGK 14881 14881
OPSS4 789 AcPTPGPAGK 9921 9921
EA2 1340 PTTDSTTPAPTTK 17462, 19493 15431
ActR-IIB 1566 GPEVTYEPPPTAPTL 17691⁎, 19722⁎ 17691
RNApII 1045 YSPTSPSKR 1045 1045
Muc5Ac 1555 GTTPSPVPTTSTTSAK 21653, 23684 17581
Neuroglycan 1340 VTAEAGSGDAQTALK 1340 1340
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in a total of 10 μL incubated at 37 °C for the times indicated in the ﬁgure
legends; CIP was added in order to avoid inhibition by the buildup of
UDP (Fritz et al., 2004), thereby mimicking Golgi apyrase (Gao et al.,
1999), while BSA was observed in preliminary experiments to stabilise
the enzymes. The amount of enzyme added was adjusted to ensure a
linear relationship of product formation over time. Incorporation of
GalNAc into peptides was determined by both MALDI-TOF MS and by
HPLC. For the latter, an Agilent 1200 LC-system equipped with a re-
versed phase ODS Hypersil 5 μm column (4 × 250 mm) was used. Sol-
vent A was 0.1% triﬂuoroacetic acid (TFA) in water, and solvent B was
0.1% TFA in acetonitrile and mixed at a ﬂow rate of 1 mL/min accordingFig. 1. Biological characterization of Xenopus xGalNAc-T6 and –T16. (A) Expression analysis b
xGalNAc-T16 is expressed in the anterior mesoderm and in the deep layer of the lateral neural
at stage 24 (see also Herr et al., 2008), GalNAc-T16 is highly expressed in the ectoderm, but excl
cement gland (cg) at stage 24. Parafﬁn sections, at the indicated positions of the stage 24 and s
stage 20 ectodermal explants isolated from embryos microinjected four times animally at the 4
and ncad indicated neuralization of the explants, xvent-2was used as a marker for active BMP
notypes of untreated Xenopus embryos and embryos microinjected twice dorsal-animally at th
tion experiments were performed at least three times (n N 25) with N70% of the embryos dis
expansion of anterior structures, in particular of the cement gland, after GalNAc-T16 injectionsto the following gradient program: 5% B for the ﬁrst 5 min, then a linear
gradient from 5–25 min of 5–15%, followed by a wash step and then a
return to the initial conditions. Elution of the unglycosylated and glyco-
sylated forms of the peptides was monitored at 210 nm.
2.6. MALDI-ToF MS/MS analysis
Assays were performed using the same basic mixture as described
above, except that 1 mM of an adapted form of the EA2 peptide with an
C-terminal arginine rather than lysine residue (PTTDSTTPAPTTR) was
employed. The products were analysed using a Bruker Autoﬂex Speed
MALDI ToF/ToF mass spectrometer (equipped with a Smartbeam™-II
laser) in positive mode; the samples were ﬁrst dried under vacuum on
a steel plate and then 6-aza-2-thiothymine (ATT) was applied twice as
matrix. Using the LIFTmode, fragmentation of parent ionswas performed
by laser-induced dissociation and 4000 shots were sampled. MS/MS
spectra were processed with the manufacturer's software (Bruker
Flexanalysis 3.3.80) using the SNAP algorithmwith a signal/noise thresh-
old of 3 (four-times smoothed).
3. Results
3.1. Developmental studies on two Xenopus GalNAc-T genes
In a previous study, the expression of four different members of the
polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family in
X. laeviswas examined by PCR; one of these genes, xGalNAc-T16 (previ-
ously known as xGalntl-1) had been identiﬁed during a screen for genes
negatively regulated by BMP signals and its tissue-speciﬁc expression
throughout early Xenopus embryogenesis was described (Herr et al.,
2008). In X. laevis, GalNAc-T16 is expressed dorsally already at gastrulay in situ hybridization of stage 12 (dorsal view) and stage 24 Xenopus embryos. Whereas
plate at stage 12 and in anterior brain, neural crest mediolateral spinal cord and notochord
uded from the neuroectoderm at stage 12 and highly expressed in the otic vesicle (ov) and
tage 12 embryos stained for xGalNAc-T6 mRNA, are shown below. (B) RT-PCR analysis of
–8 cell stage with 20 pg noggin mRNA, 100 pg op-1 mRNA or both. The expression of six3
signaling, a-actin as a marker for mesoderm and odc as a loading control. (C) Typical phe-
e 4–8 cell stage with 400 pgmRNA encoding xGalNAc-T6 or xGalNAc-T16. All microinjec-
playing an reduction of head and eye structures after overexpression of GalNAc-T6 or a
as described by Herr et al. (2008).
Fig. 2.Activity of frog xGalNAc-T6 and –T16 towards the EA2 and ActR-IIB peptides. A: The
activities of the xGalNAc-T6 (after 30 and 60min; 3.6 μg protein) and -T16 (after 2 and 4h;
13.4 μg protein)were tested invitro towards the EA2peptide andproductswere identiﬁed
by either RP-HPLC as evidenced by the appearance of a peak of lower retention time; the
inset is of an anti-FLAG Western blot of the two enzyme preparations. B: Incubations of
xGalNAc-T6 and -T16 with the ActR-IIB peptide were analysed by MALDI-TOF MS
(lower panel; products withm/z 1768 and 1972); signiﬁcant activity (ca. 10% conversion;
m/z 1769) was observed only with xGalNAc-T16, but traces of singly- and doubly-glyco-
sylated products were observed with xGalNAc-T6 (products ofm/z 1768 and 1972 were
observed with a magniﬁed scaling factor of 500).
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tube, neural crest and notochord at tadpole stages. Biochemical and
functional analysis of xGalNAc-T16 suggested that this protein regulates
mesoderm formation and neural patterning through regulation of the
TGF-β receptor ActR-IIB (Herr et al., 2008). Therefore, we compared
the expression of xGalNAc-T16 with xGalNAc-T6 during early Xenopus
development by in situ hybridization (Fig. 1a). In contrast to xGalNAc-
T16,we detected xGalNAc-T6mRNA speciﬁcally in the ventral ectoderm,
excluded from the dorsal neuroectoderm, at neurula stages and in the
cement gland, otic vesicle and ectodermat tailbud stages. The expression
pattern of xGalNAc-T16 implied transcriptional regulation by active BMP
signals. We directly addressed this question by RT-PCR studies in ecto-
dermal explants that, in isolation, differentiate autonomously in epider-
mal structures (Zimmerman et al., 1996). As expected from the in situ
analysis, only the expression of xGalNAc-T6 could be detected in untreat-
ed explants. However, this expression was abolished after overexpres-
sion of the bona ﬁde BMP antagonist Noggin (Wilson and Hemmati-
Brivanlou, 1995) and this effect was rescued after co-injection of
BMP7/OP-1mRNA (Fig. 1b). Thus, the expression of xGalNAc-T6 in ecto-
dermal explants requires active BMP signaling. Finally, animal overex-
pression of xGalNAc-T16 promotes the development of anterior (head)
structures, whereas xGalNAc-T6 overexpression resulted in a slight re-
duction of these structures (Fig. 1c).
3.2. Screening of the peptide speciﬁcities by MALDI-ToF MS
The two enzymes, xGalNAc-T6 and xGalNAc-T16, were then exam-
ined in terms of their in vitro biochemical function; both enzymes
were successfully expressed in the yeast P. pastoris as judged by tryptic
peptide mapping (data not shown) or Western blotting (Fig. 2) of the
recombinant proteins; the latter shows distinct anti-FLAG reactive
bands of around 75 kDa for xGalNAc-T6 and 60 kDa for xGalNAc-T16.
These apparent molecular weights compare well to the respective the-
oretical values of 70 kDa (with two potential N-glycosylation sites)
and 63 kDa (with no canonical N-glycosylation sites). A panel of pep-
tides was tested in a solution-based assay using MALDI-ToF MS in
order to give an overview of the substrate speciﬁcity of the two
xGalNAcT isoforms (Table 1 and Fig. 2). Peptides derived from mucin-
type proteins (Muc1, Muc5, EA2; the latter being a tandem repeat of
rat submandibular gland mucin) and artiﬁcial mucin-type peptides
(OPSS) were used as well as peptides used typically to test the activity
of other peptide-O-glycosyltransferases, such as RNApII (an O-GlcNAc-
transferase substrate) or neuroglycan (an O-xylosyltransferase sub-
strate). We also tested a peptide based on a portion of the human
ActR-IIB receptor (Gly123 to Leu137); in frog embryo explants, this recep-
tor was shown ex vivo to be directly affected by xGalNAc-T16 (Herr
et al., 2008).
In general, xGalNAc-T6 seems to accept a broader range of sub-
strates than xGalNAc-T16, with the exception of the ActR IIB peptide,
which is only poorly modiﬁed by the former enzyme (an estimated
0.2% over 2 h under the conditions used as compared to 10% by
xGalNAc-T16). On the other hand, xGalNAc-T16 incorporates just one
GalNAc residue onto seven possible glycosylation sites of the EA2 pep-
tide, whereas xGalNAc-T6 glycosylates up to three sites (Table 1);
many other mammalian isoforms incorporate up to ﬁve residues per
peptide (Pratt et al., 2004). Co-incubation of the EA2 peptide with
both enzymes did not result in an increased number of glycosylation
events (data not shown). By comparison to other studies, the mamma-
lian GalNAc-T6 has been previously shown to act on the Muc1 and EA2
peptides (Bennett et al., 1999), whereas the very recent data on mam-
malian GalNAcT-16 has been found to display signiﬁcant activity to-
wards Muc5 and EA2 (Raman et al., 2012), as well as to two domains
of Notch (Boskovski et al., 2013). Preliminary analysis of the kinetics
of the two Xenopus enzymes towards the peptide acceptors indicated
KM values of 1.0 and 2.6mM for xGalNAc-T6 and -T16with the EA2 pep-
tide and of 0.3mM for xGalNAc-T16with the ActR-IIB peptide (data notshown); this compares to KM values for EA2 of between 0.04 and 1 mM
of mammalian and invertebrate N-acetylgalactosaminyltransferases
(Ten Hagen et al., 1998, 1999).
The products of assays performed with a modiﬁed form of the
EA2 peptide (PTTDSTTPAPTTR) were analysed by MS/MS in order
to deﬁne the sites of glycosylation. As judged by the series of prob-
able y-fragments (Fig. 3), xGalNAc-T6 modiﬁed ﬁrst Thr7 of this
peptide, probably followed by Thr12 for the diglycosylated species.
On the other hand, xGalNAc-T16 appeared to solely glycosylate
Thr7 under the assay conditions employed. Previous data on other
N-acetylgalactosaminyltransferases would suggest that Thr7 is in-
deed a frequently favoured glycosylation site for those enzymes which
can accept non-glycosylated peptides as substrates; in the crystal struc-
ture of human GalNAc-T2, Thr7 of the EA2 peptide is well located to be
the glycosylated residue (Fritz et al., 2006). Also, human GalNAc-T1 and
T11 aswell as Drosophila GalNAc-T1 glycosylate either Thr6 and/or Thr7
(ten Hagen et al., 2001; Schwientek et al., 2002). The preference for
xGalNAc-T6 then glycosylating the C-terminal threonine is in line
with recent data on its bias towards singly glycosylated peptides
where the initial glycosylation has taken place at a more N-terminal
site (Gerken et al., 2013).
Fig. 3. Tandemmass spectrometric analysis of xGalNAcT products. A modiﬁed form of the EA2 peptide was employed in a MALDI-ToF-based assay and the fragmentation patterns of the
substrate (A;m/z 1345), themono- and di-glycosylated products of xGalNAc-T6 (B and C;m/z 1548 and 1751) and the sole product of xGalNAc-T16 (m/z 1548)were compared after over-
night incubation. Series of putative y-fragments are annotated with amino acids (one-letter code) commencingwith the C-terminal arginine residue (y1 ion of 175); a mass difference of
304 corresponds to a glycosylated threonine, whereas mass differences of−17 may result from loss of ammonia from y-ions. The sequences of the glycosylated peptides are shownwith
the putatively-modiﬁed threonines indicated with asterisks.
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Performing the reaction at different temperatures (16, 22, 30, 37, 42,
48 and 55 °C) with the optimized conditions described above showed
that both enzymes had their maximum activity at 42 °C (Fig. 4a). Rela-
tively few data have seemingly been published on the temperature
optimum of other recombinant N-acetylgalactosaminyltransferases; iso-
forms from Caenorhabditisweremost active at 23 °C (Hagen andNehrke,
1998), similar to data on cestode and ﬂy enzymes (EchinococcusGalNAc-
T1 at 28 °C and Drosophila GalNAc-T3 at 29–33 °C) (Freire et al., 2004;
Nakamura et al., 2004). The comparison with the temperature optima
of other glycosyltransferases (e.g., the peptide O-xylosyltransferases)
suggests that frog enzymes might have a higher temperature optimum
than for mammalian or invertebrate enzymes (Brunner et al., 2006;
Voglmeir et al., 2007). The reason for this elevated temperature maxi-
mum could be that frogs are like all other amphibians ectotherm, and
have therefore to adjust their body temperature also to many different
surroundings (Feder and Burggren, 1992). Although both isoforms
reach maximum activity at a temperature of 42 °C, xGalNAc-T6 seems
to have a slightly lower optimum than xGalNAcT-16, judged by thelower activity of the enzyme at 48 °C. However, due to reduced stability
at higher temperatures as observed in preliminary experiments, the in-
cubation temperature for other experiments was kept at 37 °C.
3.4. Metal ion requirements of xGalNAc-T6 and -T16
The metal dependency of many glycosyltransferases of the GT-A
superfamily is based on the formation of a complex between a
divalent metal ion and the oxygen atoms of the two phosphate
groups of the NDP-sugar (Breton et al., 2006). Several studies de-
scribe Mn2+ as the best activator for enzymatic activity of N-
acetylgalactosaminyltransferases, with an optimal concentration be-
tween 2.5 and 10mM(Takeuchi et al., 1985;Wang et al., 1992), where-
by reducing the concentration to 0.4 mM results in 50% loss of activity,
whereas the increase to 20, 30 and 100 mM decreases the activity to
90%, 50% and 20%, respectively (Wang et al., 1992; Mendicino and
Sangadala, 1998). Fig. 4b shows the screening of metal dependencies
of the two xGalNAcT-isoforms at a metal ion concentration of 10 mM.
Both xGalNAcT isoforms showed comparable conversion rates under
the inﬂuence of various divalent cations, H2O and EDTA. Using H2O
45J. Voglmeir et al. / Comparative Biochemistry and Physiology, Part B 180 (2015) 40–47should reveal the enzyme activity without addition of metal ions,
whereas the addition of EDTA is employed to chelate potential residual
divalent cations bound to the enzyme or divalent cations present in the
enzyme solution (Sugiura et al., 1982). No activities (less than 0.5% con-
version rate) were observed with these controls.
In general, the obtained data reﬂect the results of published studies on
mammalian N-acetylgalactosaminyltransferases. Mn2+ and Co2+
displayed the strongest stimulation of activity, whereas Ni2+, Fe2+,
Mg2+, Ca2+ and Zn2+ also stimulated to a smaller extent. xGalNAc-T6
showed a slightly higher afﬁnity for Mn2+ over Co2+ (78% activity com-
pared to Mn2+), whereas xGalNAcT-16 preferred Co2+ (Mn2+ showed
only 96% of the activity compared to Co2+). Studies which compared
the enzyme activity using Co2+ instead of Mn2+ described a decrease of
89% for murine (Elhammer and Kornfeld, 1986), 39% for porcine (Wang
et al., 1992) and 0% for bovine N-acetylgalactosaminyltransferases
(Takeuchi et al., 1985). Interestingly, the stimulation of xGalNAc-T16 by
Ni2+ seems to be much higher compared to xGalNAcT-6 (the latter's ac-
tivity being only 12% compared to the xGalNAc-T16 conversion rate).
Only the xGalNAc-T6 isoform could be stimulated by Zn2+, whereas
Ca2+ showed higher stimulation for xGalNAc-T16.
3.5. pH dependency of xGalNAc-T6 and -T16
In order to determine the pH optimum of the two recombinant en-
zymes different buffers were evaluated. Finally, MES-buffer (pH 5.0–
7.5) and AMPD-buffer (pH 7.5–9.5) were used to yield reproducible
data (in triplicate) for the determination of the pH-optimum (Fig. 4c).
Both enzymes show a relative broad pH-optimum between 5.5 andFig. 4. Biochemical characterization of frog xGalNAc-T6 and -T16. The following parame-
ters were measured for both enzymes using the EA2 peptide: (A) temperature optimum,
(B) cation dependence and (C) pH optimum. The conditions of time and enzyme dilution
were shown for both enzymes to result in the transfer of a single GalNAc residue.7.5 with maximal activities at pH 6.0. Below pH 6.0, the enzyme activi-
ties dropped steeply, while above pH 7.0, the reduction of the activities
dropped over a longer pH range. These results are in agreementwith the
expected values for enzymes located in theGolgi apparatus, considering
that the pH range in this organelle has been estimated between 5.8 and
6.6 (Wu et al., 2001). A comparison with the results on pH-optima de-
scribed in other studies indicates that both xGalNAcT-isoforms have
slightly lower pH-optima thanmammalian isoforms, whichwere deter-
mined between 6.5 and 8.2 (Takeuchi et al., 1985; Wang et al., 1992;
Mendicino and Sangadala, 1998). Indeed, in our hands, activity tests
using the recombinant human isoform 2 and MES-buffer at pH 5, 6
and 7 showed highest conversion at pH 7 (data not shown).
4. Discussion
Mucin-type O-linked glycosylation is ubiquitous in animals and is de-
ﬁned as having a ‘core’ GalNAc residue linked to serine or threonine resi-
dues, although linkage to tyrosine may also occur rarely (Steentoft et al.,
2013). After transfer of GalNAc by N-acetylgalactosaminyltransferases, a
range of different ‘cores’ can be formed which then can be further elabo-
rated. In amphibians, the O-glycan chains of a range of amphibian egg
mucins have been shown in a number of studies to be rather complex
and to display a range of unusual and extended oligosaccharide chains
(Guerardel et al., 2000). In terms of glycosyltransferases, amongst
the few from an amphibian to be previously characterised are two
N-acetylglucosaminyltransferases (GlcNAc-TI and -TII) and one
sialyltransferase (xSTX) involved in N-glycan (and not O-glycan)
biosynthesis (Kudo et al., 1998; Mucha et al., 2001, 2002); only re-
cently was a paper including enzymatic data on an amphibian N-
acetylgalactosaminyltransferase published (Boskovski et al., 2013).
On the other hand, enzymes which catalyse the ﬁrst step in mucin
biosynthesis have been studied from a number of mammalian and
invertebrate sources; obviously, the ﬁrst studies were on activities
in crude tissue extracts, but interestingly the basic properties (cation
dependency and pH optimum) are similar to those deﬁned in theFig. 5. A phylogeny of polypeptide-modifying N-acetylgalactosaminyltransferases. The
NCBI databank was searched for frog, ﬁsh, chicken, bovine, murine and human homo-
logues of GalNAc-T1 through to -T20; frog orthologues of the human T5, T8, T18 and
T20 as well as mouse and chicken homologues of T8 were not found in this search.
Highlighted are the T6 and T16 groups which are the focus of the current study.
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number of other different forms of O-glycosylation based on modiﬁ-
cation of serine and/or threonine (e.g., O-linked fucose, glucose, xy-
lose and N-acetylglucosamine), which also have important roles in
development, morphogenesis and signaling (Wilson, 2004; Zachara
and Hart, 2006; Takeuchi and Haltiwanger, 2010).
Since the expression of the ﬁrst recombinant N-acetylgalactosaminyl-
transferases 20 years ago (Hagen et al., 1993), there have been intense
efforts to characterize all members of this family (Ten Hagen et al.,
2003; Bennett et al., 2012). In the present study, we report the charac-
terization of two recombinant frog GalNAcT isoforms, xGalNAc-T6 and
xGalNAc-T16, respectively. Data on the activity and function of human
GalNAc-T16 and of one frog enzyme (xGalNAc-T11) were only
published during preparation of this manuscript (Raman et al., 2012;
Boskovski et al., 2013). In total there are sixteen N-acetyl-
galactosaminyltransferases in frog as shown by an analysis of the
whole enzyme family, including those members identiﬁed from
Xenopus tropicalis (Bennett et al., 2012), a number similar to that in
Homo sapiens, but higher than in invertebrates. Fig. 5 depicts a proposed
phylogeny of the enzymes from X. laevis, the species from which the
xGalNAc-T6 and -T16 in the current study originate, in comparison to
the ﬁsh, chicken, bovine,murine and human forms. GalNAc-T6 isoforms
group with GalNAc-T3, whereas GalNAc-T16 isoforms are close to
GalNAc-T2 and -T14; unlike some other isoforms, these can all accept
peptides which have not previously been glycosylated, which suggests
that they are N-acetylgalactosaminyltransferases which act early in
mucin biosynthesis.
Due to the high sequence similarity of comparing isoforms of differ-
ent species, similar biological functions of these enzymes in all verte-
brates can be postulated. Compatible with studies on the mammalian
isoforms, testing different acceptor substrates revealed that xGalNAc-
T6 had broader substrate speciﬁcity than xGalNAc-T16; xGalNAc-T6
showed additionally for some substrates the capacity to catalyse the
transfer of more than one GalNAc residues to certain peptides. Whereas
xGalNAc-T16 transferred only one GalNAc residue to the acceptor pep-
tide (EA2), which was used for the enzyme characterization, xGalNAc-
T6 catalysed the transfer to up to three GalNAc residues to EA2 after
overnight incubation (Table 1); this at least indirectly indicates that
this enzyme also acts on glycopeptides. A possible reason for the differ-
ences between the two enzymes might be that EA2 is not related to the
primary target peptide for xGalNAc-T16; however, the relative inability
of mammalian GalNAc-T16 to multiply glycosylate peptides and its re-
stricted substrate range have also been recently shown (Raman et al.,
2012; Kong et al., in press). The mammalian GalNAc-T6 has been previ-
ously shown to act on theMuc1 and EA2 peptides (Bennett et al., 1999),
whereas the recent data on human GalNAc-T16 has been found to dis-
play signiﬁcant activity towards Muc5, EA2 as well as peptides based
on LRP1 (low-density lipoprotein receptor related protein 1) repeats
(Raman et al., 2012; Pedersen et al., 2014). The novel substrate used
in our study, a peptide based on the sequence of human ActR-IIB, was
especially well accepted by xGalNAc-T16 with a singly-glycosylated
product being detected; themammalian enzyme, as coincidentally pub-
lished during review of this manuscript (Kong et al., in press), also has
excellent activity towards a similar sequence, suggesting conservation
of both the primary sequence and the enzymatic speciﬁcity of GalNAc-
T16 during vertebrate evolution. The activity towards the ActR-IIB pep-
tide is of interest considering the previous biological data on xGalNAc-
T16.
The twoN-acetylgalactosaminyltransferases isoforms examined here
also have different biological roles; whereas xGalNAc-T16 was shown to
inhibit a TGF-β and BMP signaling pathway by O-glycosylation of ActR-
IIB (Herr et al., 2008), TGF-β was found to increase expression of the
O-glycan-dependent oncofoetal form of ﬁbronectin and induce
epithelial-mesenchymal transition in a manner inhibited by siRNA
targettingGalNAc-T3 and -T6 (Freire-de-Lima et al., 2011). Our biochem-
ical analysis provides in vitro support the previously proposed role ofxGalNAc-T16 in the negative regulation of BMP signaling via ActR-IIB.
In particular, our data provides biochemical evidence that GalNAc-T16
might indeed directly and speciﬁcally modify ActR-IIB. In addition our
data on xGalNAc-T6 indicates that its expression is dependent on active
BMP signaling. Themicroinjection ofmRNAencoding xGalNAc-T6 result-
ed in a slight reduction of anterior structures (Fig. 1), which may imply
that xGalNAc-T6 rather promotes BMP activity. However, in loss-of-
function experiments using speciﬁc morpholino oligonucleotides no sig-
niﬁcant phenotype could be observed (unpublished data). Thus, the bio-
logical function of xGalNAc-T6 remains elusive: nevertheless, xGalNAc-
T6 displays a very distinct expression pattern and biochemical activities
as compared toGalNAc-T16. Indeed, togetherwith data fromothers indi-
cating the importance of X. tropicalis GalNAc-T11 in Notch-dependent
left-right patterning (Boskovski et al., 2013), our study shows that
there are distinct roles for different members of this large glycosyltrans-
ferase family and that Xenopus is a valuable system for examining their
contrasting biological functions during early vertebrate embryogenesis.
In the future, systematic biochemical and developmental studies on N-
acetylgalactosaminyltransferases in different systems will certainly fur-
ther aid our understanding of why there are twenty or so enzymes in
vertebrates capable of catalysing what is apparently the same reaction.
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